Client Overview A global biopharmaceutical company approached CSI to support a Phase III oncology study requiring Opdivo (nivolumab) as a comparator. The study spanned 4 countries across North America, Europe and Asia-Pacific, with a target enrolment of over 500 patients. The client’s main objective was to ensure timely delivery of branded Opdivo for multiple trial sites while maintaining transparent, full chain of custody and documentation.   Challenge There were several key

Biopharmaceuticals have seen significant advances in recent years, particularly with the development of biologics and biosimilars. These...

Oncology products monopolise the list of best-selling drugs. With a huge range of indications that is only growing, therapies become more specific to tumour or cell pathologies and increasing patient numbers. Several oncology products now have ‘blockbuster’ status where sales exceed $1 billion annually. This is relevant for clinical trials as more regulators require evidence of efficacy in comparison to the standard of care, which is likely to be one of the blockbuster produc